The Effect of Lacosamide in Peripheral Neuropathic Pain

Neuropathic Pain Clinical Trial

Official title:

The Effect of Lacosamide in Peripheral Neuropathic Pain: a Randomized, Double-blind, Placebo Controlled, Phenotype-stratified Study

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03777956
• Other study ID #: LACOSAMIDE-2018
• Secondary ID: 2018-003110-40
• Status: Terminated
• Phase: Phase 2
• Start date: January 15, 2019
• Est. completion date: June 3, 2022

Study information

• Verified date: February 2023
• Source: Danish Pain Research Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main purpose of this study is to compare the change in pain intensity during treatment with a sodium-channel blocker (lacosamide) in patients with peripheral neuropathic pain with and without the irritable nociceptor phenotype.

Description:

The main purpose of this study is to compare the change in pain intensity during treatment with a sodium-channel blocker (lacosamide) in patients with peripheral neuropathic pain with and without the irritable nociceptor phenotype. As this is a mechanistic study, the main purpose is to compare the change in pain intensity in patients who receive an expected sufficiently effective dose of lacosamide. As supportive evidence for a drug-specific predictive biomarker, the purpose is also to compare the change in pain intensity during lacosamide vs. placebo for the two phenotypes.

We hypothesize that the sodium-channel blocker lacosamide will be more effective in patients with the irritable nociceptor than those without the non-irritable nociceptor phenotype, and that lacosamide is more effective than placebo in patients with the irritable nociceptor phenotype.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 63
• Est. completion date: June 3, 2022
• Est. primary completion date: June 3, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age = 18 years.

2. Probable or definite peripheral neuropathic pain for at least 3 months (Finnerup et al. 2016)

3. Average pain intensity of at least 4 and not above 9 on a 0-10 NRS during the 7-day baseline week (Dworkin et al. 2012).

4. Written informed consent.

Exclusion Criteria:

1. Other causes of pain in the same area, or other concomitant pain that cannot be distinguished from the neuropathic pain

2. Patient who cannot cooperate or are unable to complete the project and patients who do not speak Danish.

3. Known and current cardiac conduction disturbance (2° or 3° atrioventricular (AV) block, prolonged QTc interval > 450 ms, heart rate <50 or >110 bpm, a QRS interval >120ms (ECG required)), significant cardiac, renal or liver disease or other severe illness. In patients treated with pregabalin also PQ interval > 0,2s and cardiac disease. Sitting diastolic blood pressure below 50 mmHg or above 105 mmHg.

4. Major depressive episode within 6 months, recurrent depressive disorder or other significant psychiatric disease, alcohol, illicit drug or drug abuse.

5. Pregnancy or lactation

6. Woman of childbearing potential, unless they use and acceptable effective contraception measure as defined in the Clinical Trials Facilitation Group (CTFG) during the study and at least 2 weeks after, or if their male partner is vasectomized and their sole partners. Negative pregnancy test is required.

7. Known allergy to lacosamide or excipients.

8. Concomitant pain treatment with tricyclic antidepressants, topical analgesics (lidocaine, capsaicin), lamotrigine, oxcarbazepine, cannabinoids or strong opioids that cannot be discontinued. Other treatment for neuropathic pain are allowed in a stable dose (from 14 days before randomization to completion of the trial), if they cannot be tapered off completely.

9. Concomitant treatment with products known to be associated with PQ (PR) prolongation other than pregabalin.

10. Patients inappropriate for placebo

11. Planned surgery

12. Use of sodium channel blockers within at least five half-lives and investigational drugs within 30 days.

13. Patients on controlled sodium diet, unless the amount of sodium in the capsules is acceptable for their diet.

14. The score "yes" on item 4 or item 5 of the Suicidal Ideation section of the Columbia Suicide Severity Rating Scale (C-SSRS), if the ideation occurred in the past 6 months, or "yes on any item of the Suicidal Behaviour section, except for the "Non-suicidal Self Injurious Behaviour" if this behaviour occurred in the past 2 years.

Related Conditions & MeSH terms

• Diabetic Neuropathies
• Neuralgia
• Neuropathic Pain
• Neuropathy
• Neuropathy, Diabetic
• Neuropathy, Painful
• Neuropathy;Peripheral
• Peripheral Nervous System Diseases

Intervention

Drug:
• Lacosamide
Lacosamide (50 mg) and identical placebo are given as capsules and taken orally twice a day, up to 200 mg b.i.d.
• Placebo
Identical placebo are given as capsules and taken orally twice a day.

Locations

Country	Name	City	State
Denmark	Danish Pain Research Center, Aarhus University Hospital	Aarhus

Sponsors (2)

Lead Sponsor	Collaborator
Danish Pain Research Center	Odense University Hospital

Country where clinical trial is conducted

Denmark, 

References & Publications (2)

Dworkin RH, Turk DC, Peirce-Sandner S, Burke LB, Farrar JT, Gilron I, Jensen MP, Katz NP, Raja SN, Rappaport BA, Rowbotham MC, Backonja MM, Baron R, Bellamy N, Bhagwagar Z, Costello A, Cowan P, Fang WC, Hertz S, Jay GW, Junor R, Kerns RD, Kerwin R, Kopecky EA, Lissin D, Malamut R, Markman JD, McDermott MP, Munera C, Porter L, Rauschkolb C, Rice ASC, Sampaio C, Skljarevski V, Sommerville K, Stacey BR, Steigerwald I, Tobias J, Trentacosti AM, Wasan AD, Wells GA, Williams J, Witter J, Ziegler D. Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations. Pain. 2012 Jun;153(6):1148-1158. doi: 10.1016/j.pain.2012.03.003. Epub 2012 Apr 9. — View Citation

Finnerup NB, Haroutounian S, Kamerman P, Baron R, Bennett DLH, Bouhassira D, Cruccu G, Freeman R, Hansson P, Nurmikko T, Raja SN, Rice ASC, Serra J, Smith BH, Treede RD, Jensen TS. Neuropathic pain: an updated grading system for research and clinical practice. Pain. 2016 Aug;157(8):1599-1606. doi: 10.1097/j.pain.0000000000000492. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pain intensity	The difference in the mean value of the patient's daily ratings of average pain intensity in the baseline week and the last week during treatment as experienced during the past 24 hours rated on a 0-10 point numeric rating scale (NRS; 0 = no pain, 10 = worst possible pain).; The primary objective is to compare the change in pain intensity from baseline to last week of lacosamide treatment in patients with and without the irritable nociceptor phenotype in the PP population.; The supportive objective is to compare the effect of lacosamide vs. placebo in the two phenotype groups in the PP population. Although we do not expect a phenotype difference in the response to placebo, a comparison of the effect of lacosamide vs. placebo is needed to justify that the phenotype is a predictive biomarker for the effect of lacosamide.	12 weeks
Secondary	Pain relief	(complete, good, moderate, mild, none, worse pain) . Measured at last visit/end of treatment period.	12 weeks
Secondary	Use of escape medicine (paracetamol) during treatment period.	Number of paracetamol tablets during the 12 weeks treatment period.	12 weeks